Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.
The S&P 500 added 0.4% on Monday, Nov. 18, kicking off a trading week that will feature a highly anticipated earnings report ...
HSBC analyst Yifeng Liu upgraded Moderna (MRNA) to Buy from Hold with a price target of $58, down from $82. The recent share price weakness reflects worries over the company’s path back to ...
On Thursday, Moderna Inc (MRNA) stock saw a decline, ending the day at $39.77 which represents a decrease of $-2.37 or -5.62% from the prior close of $42.14. The stock opened at $42.05 and touched a ...
In addition to Berenberg Bank, Moderna also received a Hold from HSBC’s Yifeng Liu in a report issued yesterday. However, on the same day, Piper Sandler maintained a Buy rating on Moderna ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $84.0, a ...
in.investing.com on MSN1d
Moderna stock climbs as HSBC upgrades to Buy on underestimated pipeline potentialShares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback